Wealth Club’s Post

🚀 𝐖𝐡𝐚𝐭 𝐭𝐨 𝐞𝐱𝐩𝐞𝐜𝐭: 𝐁𝐫𝐢𝐝𝐠𝐞 𝐟𝐨𝐫 𝐢𝐦𝐩𝐚𝐜𝐭! 🚀    𝐁𝐫𝐢𝐝𝐠𝐞 𝐟𝐨𝐫 𝐈𝐦𝐩𝐚𝐜𝐭 is a dynamic event organised by LifeSciences@Work and Zorginnovatie.nl that brings together innovators and entrepreneurs in life sciences & health! This event on October 15th offers entrepreneurs the opportunity to connect, share insights and explore new collaborations. ✨ Expect an inspirational keynote by Giuseppe Marzio about the use of storytelling to make your business a success, followed by multiple educational subsessions about various relevant topics 📣 Subsession 1: 1. 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐃𝐞𝐯𝐢𝐜𝐞 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐢𝐨𝐧 by Ingeborg Knol (BSI) 2. 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞𝐬 by Maarten Ligtenberg (Flindr Therapeutics) & Thom Frielink (Curie Capital BV) 3. 𝐈𝐦𝐩𝐥𝐞𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 by Eef Lamers (Micro-Cosmos) Subsession 2: 1. 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 𝐌𝐞𝐝𝐓𝐞𝐜𝐡 by Floor Waardenburg (Cue2Walk International), Douwe Jippes (Healthy.Capital) and Robert Schuman (Invest-NL) 2. 𝐄𝐱𝐩𝐥𝐨𝐫𝐢𝐧𝐠 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 by Bram Schermers (Sirius Medical) & Seth van der Meer (Post-ICU, the Digital Diary that Cares), moderated by Laura Duran (Health~Holland) 3. 𝐑𝐞𝐢𝐦𝐛𝐮𝐫𝐬𝐞𝐦𝐞𝐧𝐭 by Madelon Bracke (Clear.bio)    Want to know more about the program and the subsessions? Take a look at the program overview below! 🌐💡 Don't forget you only have 1 week left to register! 👉 https://lnkd.in/e9vjMyyp

We're thrilled to present a panel discussion at Keiretsu Forum focusing on the latest MedTech and life sciences trends. Accredited investors, this is your chance to engage with industry insiders and gain valuable insights. #KeiretsuForum #VentureCapital #MedTechInnovation

We're thrilled to present a panel discussion at Keiretsu Forum focusing on the latest MedTech and life sciences trends. Accredited investors, this is your chance to engage with industry insiders and gain valuable insights. #KeiretsuForum #VentureCapital #MedTechInnovation

🌍 𝐇𝐨𝐰 𝐂𝐚𝐧 𝐂𝐚𝐩𝐢𝐭𝐚𝐥𝐢𝐬𝐦 𝐒𝐨𝐥𝐯𝐞 𝐇𝐞𝐚𝐥𝐭𝐡 𝐈𝐧𝐞𝐪𝐮𝐢𝐭𝐲? When you think of capitalism, you probably picture profits, shareholders, and bottom lines. But what if capitalism could also solve one of the world’s biggest challenges—health inequity? That’s the question Squire Servance, founder of Syridex Bio, has been asking. His bold vision? Use the power of capitalism to tackle health disparities in underserved populations. It’s not just a dream—it’s a strategy. Here’s how Squire is doing it in 3 powerful steps: 𝐒𝐭𝐞𝐩 1: 𝐒𝐩𝐨𝐭 𝐭𝐡𝐞 𝐏𝐫𝐨𝐛𝐥𝐞𝐦 Certain diseases disproportionately affect marginalized communities, but these areas are often overlooked by big pharmaceutical companies. The result? Major gaps in care and untapped opportunities to create life-saving therapies. 𝐒𝐭𝐞𝐩 2: 𝐃𝐢𝐫𝐞𝐜𝐭 𝐂𝐚𝐩𝐢𝐭𝐚𝐥𝐢𝐬𝐦 𝐓𝐨𝐰𝐚𝐫𝐝 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬 Squire believes that profit and purpose can align. As he puts it: “𝘠𝘰𝘶 𝘤𝘢𝘯 𝘥𝘰 𝘨𝘰𝘰𝘥 𝘢𝘯𝘥 𝘥𝘰 𝘸𝘦𝘭𝘭 𝘣𝘺 𝘥𝘪𝘳𝘦𝘤𝘵𝘪𝘯𝘨 𝘤𝘢𝘱𝘪𝘵𝘢𝘭𝘪𝘴𝘮 𝘵𝘰𝘸𝘢𝘳𝘥𝘴 𝘩𝘦𝘢𝘭𝘵𝘩 𝘦𝘲𝘶𝘪𝘵𝘺.” His firm invests in therapies that address these health disparities, showing that you can generate financial returns while also tackling systemic healthcare problems. 𝐒𝐭𝐞𝐩 3: 𝐓𝐡𝐢𝐧𝐤 𝐁𝐢𝐠𝐠𝐞𝐫 Squire is already thinking about the future—beyond just treatments. From diagnostics to addressing social determinants of health, his firm is laying the groundwork to broaden its impact while staying laser-focused on delivering strong returns to investors. 💡 𝐓𝐡𝐞 𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲? You don’t have to choose between making a profit and making a difference. With the right approach, you can do both. Want to dive deeper into Squire Servance’s mission and learn how he’s transforming venture capital into a force for good? Check out the full episode here: [https://lnkd.in/dRxuQ8cK] or on Youtube [https://lnkd.in/di-t7bm2] #HealthEquity #ImpactInvesting #VentureCapital #SquireServance #SyridexBio #CapitalismForGood

Reflecting on My Journey with PingMeDoc: From Vision to Milestones On September 10th, at 1 am, I officially launched PingMeDoc—a dream I had nurtured through months of hard work and sleepless nights. Leaving my role as a doctor to pursue this vision was one of the toughest, yet most fulfilling decisions I’ve ever made. For the first month, the road was silent—no orders, no traffic—just relentless effort and faith. It tested my patience and determination. Then, last week, a breakthrough: our first organic order for a Form 1A Medical Certificate. Shortly after, another milestone—a work-from-home certificate order from Panama, our first international client. These milestones, though small, are monumental to me. They reaffirm that resilience and persistence are the true foundations of success. To anyone building from scratch: keep going. The silence is just the start, and when the first signs of growth emerge, they bring unparalleled joy. As I continue to grow PingMeDoc, I’m excited to connect with fellow dreamers and professionals. Your support, insights, and shared stories inspire me to push boundaries and dream bigger. Here’s to celebrating every milestone—big or small—and making an impact, one step at a time. Let’s grow together! 💪✨ #PingMeDoc #FounderJourney #Entrepreneurship #HealthcareInnovation #Milestones #Resilience #AIInHealthcare

After a productive networking break in the Great Room Foyer, we now have the “Medtech by the Numbers” Panel Session, moderated by Jennifer McMahon, Partner at Seroba.: • Inga D. Deakin, Principal, Molten Ventures • Megan MacDonagh, Vice President, SV Health Investors • Anne Portwich, Partner, EQT Life Sciences  • Sylvain Sachot, Partner, Asabys Partners 2023 life science investment went down across the board, in biotech and medtech equally, but in diagnostics and healthtech to a greater degree. A panel of European VCs discusses what’s in store for 2024. The number of up-rounds is down, which is a negative for VC firms supporting early-stage companies. The situation needs to change in order to reward early investment, the lifeblood of medtech innovation. We are seeing a lot of structured deals, option deals with many milestones. It does look good when a strategic is interested in a company, and it provides a path for exit. But it is a two-sided sword.   Remain informed on new articles, conference updates and more with our helpful medtech community newsletter. Subscribe here: https://bit.ly/42KHJKI

☄️This really was a fascinating conversation about making a dent in the universe. I've always had 'ideas' about fixing healthcare from the outside in - but never really thought seriously about entrepreneurship. I think this was mainly because baking into the culture of medicine. Entrepreneurship was never really seen as a serious option. I had no grounded understanding or mentors to follow. You have to break so many cultural norms in medicine to put your hand up and take that brave step to go out on your own. That's why I enjoyed our conversation so much. Josh does a great job dispelling many myths in this space and highlights how ANYONE can learn to be an inventor. My time at Stanford further emphasised this positive, ambitious and optimistic approach to solving big problems yourself - as every second post-grad I spoke to wanted to change the world. I hope this inspires a few more Clinicians to learn from Josh and the Stanford Byers Center for Biodesign methods of innovation and design! To listen to the full episode: 📙Substack: https://lnkd.in/gxmqPnQK 🍎 Apple: https://lnkd.in/gbKh3iwm

More interesting thoughts from Darwin Ling in the Bullpen Inning 1.

🌟 Exciting News! 🌟 Please join us in welcoming Dr. Karolina Valente from VoxCell BioInnovation as one of our newest Ventures in the Growth initiative! We’re thrilled to have Karolina and her team on board and can’t wait to see their continued success unfold. Check out Karolina's message below to hear what she’s most excited about as she embarks on this journey with us. ✨ #WomenInTech #FemaleFounders #TechEntrepreneurs #StartupWomen #WomenInBusiness #FemaleEntrepreneurs

Dimension closes a second fund at a stunning $500 million total #Dimension, a New York City-based #VC firm, has announced the successful close of its second fund at $500 million. This milestone highlights Dimension's commitment to supporting founders at the intersection of technology and life sciences. Led by Nan Li, Zavain Dar, and Adam Goulburn, the firm collaborates closely with entrepreneurs, academics, and engineers to transform groundbreaking ideas into impactful businesses. Dimension's portfolio reflects its focus on the convergence of tech and bio innovation, featuring companies like Chai Discovery, Monte Rosa Therapeutics, Automata, and NewLimit. With this significant new fund, Dimension is set to deepen its engagement in the tech-bio ecosystem, fueling the next wave of transformative solutions across sectors. The article on #VCwiretech in the first comment.